| Literature DB >> 27859268 |
Andrea Burón Pust1,2,3,4, Rupert Alison1, Roger Blanks1, Kirstin Pirie1, Kezia Gaitskell1, Isobel Barnes1, Toral Gathani1, Gillian Reeves1, Valerie Beral1, Jane Green1.
Abstract
Associations between behavioural and other personal factors and colorectal cancer risk have been reported to vary by tumour characteristics, but evidence is inconsistent. In a large UK-based prospective study we examined associations of 14 postulated risk factors with colorectal cancer risk overall, and across three anatomical sites and four morphological subtypes. Among 1.3 million women, 18,518 incident colorectal cancers were identified during 13.8 (SD 3.4) years follow-up via record linkage to national cancer registry data. Cox regression yielded adjusted relative risks. Statistical significance was assessed using correction for multiple testing. Overall, colorectal cancer risk was significantly associated with height, body mass index (BMI), smoking, alcohol intake, physical activity, parity and menopausal hormone therapy use. For smoking there was substantial heterogeneity across morphological types; relative risks around two or greater were seen in current smokers both for signet ring cell and for neuroendocrine tumours. Obese women were also at higher risk for signet ring cell tumours. For adenocarcinomas, the large majority of colorectal cancers in the cohort, all risk factor associations were weak. There was little or no heterogeneity in risk between tumours of the right colon, left colon and rectum for any of the 14 factors examined. These epidemiological findings complement an emerging picture from molecular studies of possible different developmental pathways for different tumour types.Entities:
Keywords: colorectal cancer; risk factors; smoking; subtype
Mesh:
Substances:
Year: 2017 PMID: 27859268 PMCID: PMC5347941 DOI: 10.1002/ijc.30527
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396
Characteristics of women at recruitment, and follow‐up for incident colorectal cancer
|
|
| |
|---|---|---|
|
|
| |
| Age (yr) | ||
| Mean (SD) | 56.1 (4.6) | 57.6 (4.7) |
| Socioeconomic status | ||
| % Most deprived tertile | 33.3 | 33.4 |
| Height (cm) | ||
| Mean (SD) | 162.0 (6.7) | 162.5 (6.7) |
| Body mass index (kg/m2) | ||
| Mean (SD) | 26.2 (4.7) | 26.4(4.7) |
| Smoking | ||
| % Current | 20.6 | 19.9 |
| Alcohol | ||
| %15 + units/wk | 5.0 | 5.7 |
| Strenuous physical activity | ||
| %1 + /wk | 38.9 | 36.6 |
| Age at menarche | ||
| % 15+ yr | 17.0 | 17.9 |
| Parity | ||
| % Nulliparous | 10.8 | 11.7 |
|
| ||
| %3+ | 37.0 | 39.0 |
| Hysterectomy | ||
| % Yes | 25.0 | 24.3 |
| Sterilisation | ||
| % Yes | 23.2 | 21.7 |
| Age at menopause (yr) | ||
| Mean (SD) | 47.5 (6.1) | 49.4 (4.7) |
| Oral contraceptive use | ||
| % Ever | 33.2 | 29.9 |
| Hormone therapy use | ||
| % Ever | 50.5 | 46.9 |
| Years of follow‐up | ||
| Mean (SD) | 13.8 (3.4) | 8.8 (4.3) |
| Age at cancer diagnosis (yr) | ||
| Mean (SD) | – | 66.9 (6.2) |
In parous women.
In never HT users.
In postmenopausal women.
Distribution of colorectal cancers by site and by morphology
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| Caecum | 2,212 | 288 | 25 | 63 | 232 | 2,820 |
| Appendix | 39 | 85 | 8 | 87 | 14 | 233 |
| Ascending colon | 1,378 | 176 | 18 | 6 | 93 | 1,671 |
| Hepatic flexure/transverse colon | 1,263 | 146 | 14 | 3 | 128 | 1,554 |
|
|
|
|
|
|
|
|
| Splenic flexure/descending colon | 846 | 74 | 6 | 0 | 65 | 991 |
| Sigmoid colon | 3,846 | 180 | 4 | 10 | 238 | 4,278 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recto‐sigmoid | 1,228 | 47 | 8 | 2 | 84 | 1,369 |
| Rectum | 3,850 | 188 | 14 | 48 | 288 | 4,388 |
|
|
|
|
|
|
|
|
Relative risks (RRs) and 95% confidence intervals (CIs) for incident colorectal cancer in relation to 14 socioeconomic and behavioural factors
|
|
|
| |
|---|---|---|---|
|
| |||
| Least deprived | 6,040 | Reference | |
| Mid tertile | 6,221 | 1.03 (0.99–1.07) |
|
| Most deprived | 6,146 | 1.03 (0.99–1.07) | |
|
| |||
| <160 | 5,438 | Reference | |
| 160–164.9 | 5,444 | 1.12 (1.08–1.16) |
|
| 165+ | 7,333 | 1.25 (1.21–1.30) | |
|
| |||
| <25 | 7,751 | Reference | |
| 25–29.9 | 6,523 | 1.07 (1.04–1.11) |
|
| 30+ | 3,262 | 1.11 (1.06–1.15) | |
|
| |||
| Never | 8,610 | Reference | |
| Past | 5,385 | 1.15 (1.11–1.19) |
|
| Current <15/d | 1,797 | 1.13 (1.07–1.19) | |
| Current 15+/d | 1,668 | 1.19 (1.13–1.26) | |
|
| |||
| 0–2 | 10,947 | Reference | |
| 3–14.9 | 6,389 | 1.04 (1.01–1.08) |
|
| 15+ | 1,049 | 1.25 (1.17–1.33) | |
|
| |||
| Rarely/never | 9,112 | Reference | |
| Once per week | 5,222 | 0.95 (0.91–0.98) |
|
| >Once per week | 3,498 | 0.90 (0.87–0.94) | |
|
| |||
| <13 | 6,833 | Reference | |
| 13–14 | 8,063 | 0.96 (0.93–0.99) |
|
| 15+ | 3,238 | 0.98 (0.93–1.02) | |
| Parity | |||
| Nulliparous | 2,166 | Reference |
|
| Parous | 16,310 | 0.91 (0.87–0.95) | |
|
| |||
| 1 | 2,612 | Reference | |
| 2 | 7,341 | 0.97 (0.92–1.01) |
|
| 3+ | 6,357 | 0.99 (0.95–1.04) | |
|
| |||
| No | 13,916 | Reference |
|
| Yes | 4,461 | 0.96 (0.92–1.00) | |
|
| |||
| No | 14,043 | Reference |
|
| Yes | 3,895 | 0.99 (0.96–1.03) | |
|
| |||
| <45 | 900 | Reference | |
| 45–49 | 1,949 | 0.93 (0.86–1.01) |
|
| 50+ | 4,098 | 0.97 (0.90–1.04) | |
|
| |||
| Never | 8,422 | Reference | |
| <5 | 4,403 | 0.98 (0.94–1.02) |
|
| 5+ | 5,479 | 0.99 (0.95–1.02) | |
|
| |||
| Never | 7,134 | Reference |
|
| Ever | 4,130 | 0.94 (0.90–0.98) | |
In postmenopausal never HT users.
In postmenopausal women.
Figure 1Relative risks (RRs) and 95% confidence intervals (CIs) for incident colorectal cancer in relation to selected risk factors, by anatomic site. All tests for heterogeneity are non‐significant (p > 0.05) after Holm‐Bonferroni correction for multiple testing BMI, body mass index; HT, hormone therapy for menopause; pw, per week
Figure 2Relative risks (RRs) and 95% confidence intervals (CIs) for incident colorectal cancer in relation to selected risk factors, by morphology. Tests for heterogeneity are non‐significant (p > 0.05) after Holm‐Bonferroni correction for multiple testing, except where indicated by *p > 0.05. BMI, body mass index; HT, hormone therapy for menopause; pw, per week